STOCK TITAN
  1. Home
  2. News
  3. TTOO

T2 Biosystems Inc - TTOO STOCK NEWS

Welcome to our dedicated news page for T2 Biosystems (Ticker: TTOO), a resource for investors and traders seeking the latest updates and insights on T2 Biosystems.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect T2 Biosystems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of T2 Biosystems's position in the market.

News
T2 Biosystems Announces Reverse Stock Split Effective Today
Rhea-AI Summary
T2 Biosystems announces reverse stock split
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43.87%
Tags
none
-
News
T2 Biosystems Reports Granting of Inducement Award
Rhea-AI Summary
T2 Biosystems issues inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023
Rhea-AI Summary
T2 Biosystems to report Q3 2023 financial results and business updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.57%
Tags
conferences earnings
News
T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel
Rhea-AI Summary
T2 Biosystems receives FDA clearance for T2Biothreat Panel, allowing immediate marketing and sales in the US market. Panel detects six biothreat pathogens with high sensitivity and specificity. Clinical evaluation shows positive percent agreement of 100% for most targets. Pathogens detected can result in high mortality rates. Rapid and accurate diagnostic testing expected to play a key role in targeted antimicrobial treatment and minimizing economic impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.14%
Tags
clinical trial
-
News
T2 Biosystems Reports Granting of Inducement Award
Rhea-AI Summary
T2 Biosystems issues inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
T2 Biosystems to Participate in the Gilmartin Group Emerging Growth Company Showcase
Rhea-AI Summary
T2 Biosystems to participate in Gilmartin Group Emerging Growth Company Showcase
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.66%
Tags
conferences acquisition
News
T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs
Rhea-AI Summary
CDC releases Hospital Sepsis Program Core Elements to optimize sepsis programs in the US. T2 Biosystems praises the action and highlights the benefits of their products in rapid sepsis detection. Sepsis is the leading cause of death in US hospitals, costing $62 billion annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.97%
Tags
none
-
News
T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement
Rhea-AI Summary
T2 Biosystems regains compliance with NASDAQ market value requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.65%
Tags
none
-
News
T2 Biosystems Announces Second Quarter 2023 Financial Results
Rhea-AI Summary
T2 Biosystems received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel orders, and received second-largest sepsis driven T2Dx Instrument order. Q2 total revenue decreased by 67%, primarily due to reduction in BARDA research contribution revenues. Cash and cash equivalents totaled $16.1 million as of June 30, 2023. The Company expects full-year sepsis and related product revenue growth of 13% to 25% compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.53%
Tags
earnings
News
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements
Rhea-AI Summary
T2 Biosystems, Inc. has been granted an extension by the Nasdaq Hearings Panel to evidence compliance with Nasdaq's minimum bid price and market value of listed securities requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.59%
Tags
none
Stock TTOO logo
T2 Biosystems Inc

Nasdaq:TTOO

TTOO Rankings

#5061 Ranked by Market Cap
#5524 Ranked by Stock Gains
N/A Ranked by Dividends

TTOO Stock Data

17.31M
4.66M
6.76%
19.28%
7.2%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
US
Lexington

About TTOO

t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www